Mo A - Search Results

1

Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review.

Mo A, Poynton M, Wood E, Shortt J, Brunskill SJ, Doree C, Sandercock J, Saadah N, Luk E, Stanworth SJ, McQuilten Z. Mo A, et al. Blood Rev. 2023 Sep;61:101114. doi: 10.1016/j.blre.2023.101114. Epub 2023 Jul 13. Blood Rev. 2023. PMID: 37479599 Free article. Review.

2

Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials.

Mo A, McQuilten ZK, Wood EM, Weinkove R. Mo A, et al. Intern Med J. 2017 Jun;47(6):695-698. doi: 10.1111/imj.13434. Intern Med J. 2017. PMID: 28580745

3

Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial.

Stanworth SJ, Killick S, McQuilten ZK, Karakantza M, Weinkove R, Smethurst H, Pankhurst LA, Hodge RL, Hopkins V, Thomas HL, Deary AJ, Callum J, Lin Y, Wood EM, Buckstein R, Bowen D; REDDS Investigators. Stanworth SJ, et al. Br J Haematol. 2020 Apr;189(2):279-290. doi: 10.1111/bjh.16347. Epub 2020 Jan 20. Br J Haematol. 2020. PMID: 31960409 Free article. Clinical Trial.

4

Red cell transfusions: Is less always best?: How confident are we that restrictive transfusion strategies should be the standard of care default transfusion practice?

Mo A, Stanworth SJ, Shortt J, Wood EM, McQuilten ZK. Mo A, et al. Transfusion. 2021 Jul;61(7):2195-2203. doi: 10.1111/trf.16429. Epub 2021 Jun 1. Transfusion. 2021. PMID: 34075594 Review. No abstract available.

5

Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes.

Mo A, Wood E, Shortt J, Hu E, McQuilten Z. Mo A, et al. Eur J Haematol. 2023 Oct;111(4):592-600. doi: 10.1111/ejh.14049. Epub 2023 Jul 15. Eur J Haematol. 2023. PMID: 37452616 Free PMC article.

6

Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey.

Mo A, Weinkove R, Wood EM, Shortt J, Johnston A, McQuilten ZK; Australasian Leukaemia and Lymphoma Group Supportive Care Scientific Working Party. Mo A, et al. Eur J Haematol. 2024 Apr;112(4):621-626. doi: 10.1111/ejh.14156. Epub 2023 Dec 20. Eur J Haematol. 2024. PMID: 38123137

7

Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes.

Mo A, Wood E, Shortt J, Charlton A, Evers D, Hoeks M, Pritchard E, Daly J, Hodgson C, Opat S, Bowen D, Reynolds J, Thi Phung Thao L, Stanworth SJ, McQuilten Z. Mo A, et al. Transfusion. 2024 Feb;64(2):236-247. doi: 10.1111/trf.17706. Epub 2024 Jan 12. Transfusion. 2024. PMID: 38214417

8

Early radiological intervention and haematology screening is associated with excellent outcomes in Budd-Chiari syndrome.

Mo A, Testro A, French J, Robertson M, Angus P, Grigg A. Mo A, et al. Intern Med J. 2017 Dec;47(12):1361-1367. doi: 10.1111/imj.13544. Intern Med J. 2017. PMID: 28675622

9

Restrictive transfusion thresholds: Have we left patient-centered outcomes behind?

Mo A, Higgins AM. Mo A, et al. Transfusion. 2022 Oct;62(10):1929-1932. doi: 10.1111/trf.17105. Epub 2022 Sep 19. Transfusion. 2022. PMID: 36120958 No abstract available.

10

The importance of ABO in platelet refractoriness, an often overlooked option.

Gammon R, Mo A. Gammon R, et al. Among authors: mo a. Br J Haematol. 2024 May;204(5):1602-1604. doi: 10.1111/bjh.19435. Epub 2024 Mar 28. Br J Haematol. 2024. PMID: 38544441

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

307 results

Search Page